The Blue Box Biomedical Solutions logo

The Blue Box Biomedical Solutions Funding & Investors

Women aged 20-45 cannot get screened for breast cancer because existing solutions are unreliable. However, 81% want to. At The Blue Box, we have built a pain-free, low-cost, sensitive, radiation-free device to detect breast cancer in urine with a sensitivity of 83%. In 2024, we’ll launch into the market, bringing The Blue Box to private gynecology clinics with a Diagnostics-as-a-Service subscription model, and a pay-per-test revenue stream that we’ll share with doctors.

thebluebox.ai

Total Amount Raised: $2,102,110

The Blue Box Biomedical Solutions Funding Rounds

  • Pre Seed

    322,702 EUR

  • Grant

    661,156 EUR

  • Seed

    540,631 EUR

    Seed Investors

    Grow Venture Partners
    Unconventional Ventures
  • Grant

    333,967 EUR

  • Pre Seed

    156,330 EUR

  • Pre Seed

    87,324 EUR

Funding info provided by Diffbot.